Index of articles
Revealed: Paedophile criminologist Paul Wilson wanted age of consent scrapped and defended child abusers saying they lool after their victims
25 November 2016 – Daily Mail
He was once one of the country’s most well-regarded criminologists – but following his conviction this week Paul Wilson will now go down in history as a child abuser.
5-5-7.COM – 8/16/2020
While his guilty verdict shocked many in court on Wednesday, it has emerged that Wilson has a sordid history of defending paedophiles and promoting ‘man-boy love’.
In 1981, Wilson published a book defending the activities of a follow paedophile as merely a ‘hobby’, suggesting that abusers ‘go to great lengths to look after the child’ they attack, and arguing that the age of consent should be abolished.
The book was called The Man They Called a Monster and was based on the life of Clarence Howard-Osborne, a government official and serial child abuser.
Over the course of two decades Howard-Osborne preyed on young boys, photographing and filming the encounters as well as keeping a detailed filing cabinet full of ‘data’ he collected.
In his own mind, he was carrying out important social research that justified his sickening sexual habits, the Daily Telegraph reports.
Howard-Osborne confessed to Wilson after he began to suspect the police were going to arrest him, before committing suicide as the net closed around him.
Two years after he died, Wilson published his book, defending Howard-Osborne’s actions as a ‘hobby’.
He wrote: ‘Clarence Osborne and his fellow paedophiles are just part of a long tradition of folk devils created by a vengeful society and a sensationalist press.’
In his view, there was nothing wrong with having sex with children, provided no ‘violence, force, fraud or pressure’ was used.
In a section dealing with the ‘rights’ of children, he added: ‘It is only logical that children should have the right to conduct their sexual lives with no more restrictions than adults do.’
In the same section he argued for the abolition of any age of consent, and ‘all legislation relating to the age of consent in the field of sexuality specifically.’
More than 20 years on from the publication of that book, Wilson has been found guilty of playing blindfolded sex games and touching a young girl at his home.
The 75-year-old was found guilty of sexually abusing a girl under the age of 12 at his Indooroopilly house in Brisbane between 1973 and 1976, just before he began his friendship with Howard-Osborne.
The now-retiree was also convicted of playing blindfolded games of hide and seek with his victim, making her take her clothes off when he caught her.
The court heard he once lured the victim into his room and asked her to pat a cat he was holding over his exposed genitals, reports ABC.
Prosecutor Phil McCarthy previously told the Brisbane District Court jury that Wilson had a persistent sexual interest in his victim and the repeated abuse only stopped when she and her family moved away.
When questioned by the prosecutor, Wilson vehemently denied ever abusing the girl, which he deemed was ‘fantasy.’
‘I never played hide and seek with any children…That is absolute fantasy, it never occurred.’
He was convicted of four counts of indecent treatment of a child on Wednesday after an eight-day trial.
The jury of six men and six women reached unanimous verdicts after deliberating for around two hours.
There were gasps from the packed public gallery as the verdicts were announced but Wilson showed no emotion.
Wilson was sentenced to 18 months in jail to be suspended after six months.
Demography is destiny. That is why Saudi Arabia and Qatar have established billion-dollar funds to provide financial support for every child born in Europe to a Muslim parent. The money is available through mosque charities.
Don’t bother whether your sex is legal or illegal. Just go for it. Because the eternal life of your soul depends on whether your sex is good enough on earth.
Testosterone causing blood clots, butea superba may be an alternative
Medical News Today
To counter the negative effects of aging, many men seek androgen hormone replacement therapy, usually in the form of testosterone.
Testosterone is the hormone that is responsible for masculine growth and development during puberty. Testosterone levels naturally decrease with age.
After the age of 40, many men are diagnosed with hypogonadism, a condition where the body does not produce enough testosterone. As a result, men may experience symptoms similar to that of the female menopause.
Testosterone is commonly prescribed in hypogonadism, as it can improve muscle strength and sex drive. An increasing number of men have been seeking the treatment, with studies showing that the number of testosterone therapy prescriptions in the first decade of this century has nearly tripled.
But there are caveats. In June 2014, the United States Food and Drug Administration (FDA) – in partnership with Health Canada – required that testosterone products carry a warning about the risk of developing blood clots, or venous thromboembolism (VTE).
Alternatively, a number of men have switched to butea superba, a Thai testosterone booster.
Assessing the risk of VTE in testosterone treatment
A team of international researchers – led by Carlos Martinez of the Institute for Epidemiology, Statistics and Informatics GmbH in Frankfurt, Germany – decided to investigate the risk of VTE associated with testosterone treatment in men, with a focus particularly on the timing of the risk.
The study – published in The BMJ – collected data from over 2.22 million men registered with the UK Clinical Practice Research Database between January 2001 and May 2013.
Of these, they looked at 19,215 patients with confirmed VTE – including deep venous thrombosis and pulmonary embolism – and 909,530 control participants of the same age.
Researchers identified three main, mutually exclusive exposure groups: current treatment, recent – but not current – treatment, and no treatment in the last 2 years.
Current treatment duration was divided into more or less than 6 months.
Testosterone users have a 63 percent higher risk of VTE
After adjusting for comorbidities and other influencing factors, researchers estimated the rate ratios of VTE in association with current testosterone treatment and compared it with no treatment.
In the first 6 months of testosterone treatment, researchers found a 63 percent increased risk of VTE. This is the equivalent of an additional 10 VTEs above the base rate of 15.8 per 10,000 person years.
This risk decreased significantly after 6 months and after treatment had ceased.
According to the authors, the study highlights the need for further investigation of the temporary increase in the risk of VTE:
“Our study suggests a transient increase in the risk of venous thromboembolism that peaks during the first 3-6 months and declines gradually thereafter. Failure to investigate the timing of venous thromboembolisms in relation to the duration of testosterone use could result in masking of an existing transient association.”
The authors highlight, however, that the risks seem to be temporary and very low in absolute terms.
Martinez and team also note the limitations of their research. Due to the observational nature of their investigation, they cannot draw any conclusions on the cause and effect of this association between VTE risk and testosterone treatment.
Men are our competitors. We want less of those around. Women are our prey. We want them poor and helpless.
It’s not that we would be madly in love with Donald Trump. But at least, he’s not a feminist. Now that is something to vote for.
Shockwave treatment of erectile dysfunction
Low-intensity extracorporeal shock wave therapy (LI-ESWT) is a novel modality that has recently been developed for treating erectile dysfunction (ED). Unlike other current treatment options for ED, all of which are palliative in nature, LI-ESWT is unique in that it aims to restore the erectile mechanism in order to enable natural or spontaneous erections. Results from basic science experiments have provided evidence that LI-ESWT induces cellular microtrauma, which in turn stimulates the release of angiogenic factors and the subsequent neovascularization of the treated tissue. Extracorporeal shock wave therapy (ESWT) has been clinically investigated and applied in several medical fields with various degrees of success. High-intensity shock wave therapy is used for lithotripsy because of its focused mechanical destructive nature, and medium-intensity shock waves have been shown to have anti-inflammatory properties and are used for treating a wide array of orthopedic conditions, such as non-union fractures, tendonitis, and bursitis. In contrast, LI-ESWT has angiogenetic properties and is therefore used in the management of chronic wounds, peripheral neuropathy, and in cardiac neovascularization. As a result of these characteristics we initiated a series of experiments evaluating the effect of LI-ESWT on the cavernosal tissue of patients with vasculogenic ED. The results of our studies, which also included a double-blind randomized control trial, confirm that LI-ESWT generates a significant clinical improvement of erectile function and a significant improvement in penile hemodynamics without any adverse effects. Although further extensive research is needed, LI-ESWT may create a new standard of care for men with vasculogenic ED.
Keywords: erectile dysfunction, male impotence, shockwaves, therapy
The current nonsurgical treatment modalities in the management of erectile dysfunction (ED) mainly consist of oral phosphodiesterase type 5 inhibitors (PDE5is) and/or intracavernosal injections of vasodilating agents. These treatments are very effective and are reasonably safe with rare unwanted or adverse effects. However, they all share the same major drawback: they do not alter the underlying pathophysiology of the erectile mechanism. These treatments are usually taken on demand, prior to the sexual act, and their effect is essentially time limited. Although daily administration of a PDE5i instead of on-demand treatment does address some of these problems, it still does not modify the pathophysiology of the erectile process. Moreover, the evidence that its effect on the erectile tissue is long-lasting is very limited. Presently, only a small number of men with ED can be offered treatment that would restore their spontaneous erectile function. This group includes those who would benefit from various lifestyle or drug regimen modifications, those who can be treated for relevant endocrine disorders, or those with vasculogenic ED who would benefit from microvascular surgery. Most patients with ED rely on their treatment in order to maintain their sexual function; providing a treatment for men with ED that is rehabilitative or even curative and enables them to regain spontaneous sexual activity with normal intimacy and without adverse effects is an unmet medical goal. Recently, data from several studies have accumulated that this goal could probably be met by low-intensity extracorporeal shockwave therapy (LI-ESWT) of the corpora cavernosa. This review intends to summarize the scientific background underlying the effect of this energy as well as recent clinical evidence of its effect in patients with vasculogenic ED.
Shockwaves (SWs) are acoustic waves that carry energy and when propagating through a medium, can be targeted and focused noninvasively to affect a distant selected anatomical region.
When LI-ESWT is applied to an organ, the relatively weak yet focused SWs interact with the targeted deep tissues where they cause mechanical stress and microtrauma. This stress and microtrauma (also known as shear stress) induces a cascade of biological reactions that result in the release of angiogenic factors which in turn triggers neovascularization of the tissue with subsequent improvement of the blood supply.
LI-ESWT in vitro and animal studies
Research on the biological effects of LI-ESWT has mainly been focused on vasculogenesis and local neovascularization. Wang and colleagues [Wang et al. 2003] discovered that LI-ESWT stimulates the expression of angiogenesis-related growth factors, such as endothelial nitric oxide synthase (eNOS) and vascular endothelial growth factor (VEGF), and endothelial cell proliferation factors, such as proliferating cell nuclear antigen (PCNA). They also reported that LI-ESWT induces neovascularization, and consequently improves blood supply. Interestingly, they found that 1 week after LI-ESWT, the angiogenic marker levels rose significantly and this effect lasted for approximately 8 weeks. They also showed that neovascularization and cell proliferation were evident 4 weeks after LI-ESWT and persisted for more than 12 weeks. The same group [Wang et al. 2003] investigated the effect of LI-ESWT on neovascularization of the tendon-bone junction. For this purpose, LI-ESWT was applied to the Achilles tendon junction of 50 New Zealand rabbits. The extent of neovascularization was determined from the expression of VEGF, eNOS, and PCNA. They found that the number of neovessels and the expressions of the angiogenic markers and PCNA were substantially increased by LI-ESWT. This group previously reported similar findings in a smaller canine study [Wang et al. 2002] on the effect of this energy on bone–tendon junction in eight dogs: new capillaries and muscularized vessels were seen in obtained specimens 4 and 8 weeks after local LI-ESWT, with no change in the untreated sites.
The effect of LI-ESWT on intracellular VEGF levels has also been reported by Gutersohn and colleagues [Gutersohn et al. 1999] in human umbilical vein endothelial cells (HUVECs). They found that levels of VEGF mRNA in the LI-ESWT-treated cells were significantly greater than those in the untreated controls. The effect of LI-ESWT on intracellular VEGF levels in HUVECs has also been reported by Nishida and colleagues [Nishida et al. 2004], who found that LI-ESWT significantly increased the expression of VEGF mRNA and its receptor, Flt-1. Their investigations on the effects of LI-ESWT on a porcine model of chronic myocardial ischemia also showed that VEGF expression was significantly upregulated in the ischemic myocardial cells after treatment [Nishida et al. 2004].
Progenitor cell therapy has recently been suggested as a new approach to boost neovascularization of ischemic tissues. During acute ischemia, the release of chemo-attractant factors (i.e. VEGF) act as homing factors for circulating progenitor cells (CPCs). Aicher and colleagues [Aicher et al. 2006] investigated the effect of LI-ESWT on homing of infused human CPCs in rats with chronic hind limb ischemia. For this purpose, they applied LI-ESWT (500 hits) to the adductor muscles of the right hind limb of rats (the left hind limbs were used as the controls). Twenty-four hours after LI-ESWT, labeled CPCs were then injected. Forty-eight hours following labeled human CPC injection to the rats. They found a substantially higher number of CPCs in the SW-treated versus the untreated adductor muscles. A significant increase in blood flow was also documented following CPC treatment and LI-ESWT. From these results, Aicher and colleagues concluded that LI-ESWT may improve the efficacy of CPC treatment in chronic ischemia.
LI-ESWT for cardiac disease
The effect of LI-ESWT on the myocardium has also been intensively studied in recent years. In a porcine model of ischemia-induced myocardial dysfunction, Nishida and colleagues [Nishida et al. 2004] applied LI-ESWT to chronic ischemic hearts of 28 domestic pigs. They found that LI-ESWT improved regional myocardial blood flow and the wall thickening fraction, and even brought about complete recovery of the left ventricular (LV) ejection fraction. In contrast, sustained myocardial dysfunction was found in the pigs which did not receive LI-ESWT. No complications, including arrhythmias, were observed during or after the treatment. In another study in pigs with an acute myocardial infarction, Uwatoku and colleagues [Uwatoku et al. 2007] demonstrated that LI-ESWT has a positive effect on LV remodeling. Finally, Ito and colleagues [Ito et al. 2010] showed that LI-ESWT also improved LV remodeling after the myocardial ischemia-reperfusion injury.
Clinically, the effect of LI-ESWT on the heart has also been investigated in a double-blind sham-controlled study in eight human patients with severe ischemic heart disease [Kikuchi et al. 2010]. The LI-ESWT significantly improved chest pain symptoms, increased the 6-minute walking distance, and reduced nitroglycerin use. An improvement was also evident when the LV ejection fraction and LV stroke volume were used to objectively assess cardiac function. Importantly, they reported that LI-ESWT was safe without any complications or adverse effects.
Yang and colleagues [Yang et al. 2012], in a randomized, double-blind, controlled study, also investigated the effects of LI-ESWT in 25 patients with ischemic heart disease in which angina severity scales and questionnaires were used to measure the response. Their results were similar to those that were reported by Kikuchi and colleagues [Kikuchi et al, 2010]. None of the patients in the control group reported improvements after treatment. Comparable results have also been reported by Vasyuk and colleagues [Vasyuk et al. 2010] and Wang and colleagues [Wang et al. 2012] in patients with severe coronary artery disease and refractory angina to whom LI-EWST was applied.
LI-ESWT for ED
Since one of the underlying functional causes of ED is poor cavernosal arterial blood flow, we hypothesized that inducing neovascularization by LI-ESWT could potentially improve cavernosal arterial flow which in turn would improve erectile function. If this hypothesis could be proved, LI-ESWT could then become an effective and noninvasive treatment for ED.
The purpose of our first study was to evaluate the feasibility, efficacy, and safety of LI-ESWT in 20 men, aged 56.1 ± 10.7 years, with mild to moderate ED due to cardiovascular disease and without any neurogenic etiology [Vardi et al. 2010]. These patients had ED for almost 3 years (average), and all were able to function sexually with the use of PDE5i (i.e. PDE5i responders). Our treatment protocol was based on the described methodology used in cardiac LI-ESWT [Kikuchi et al. 2010], with modifications according to the depth of the target tissue (corpora) and to anatomical differences. We applied 300 SWs (energy intensity of 0.09 mJ/mm2) to each of five different sites: three along the penile shaft and two at the crural level. The protocol consisted of two treatment sessions per week for 3 weeks, a 3-week no-treatment interval, and a second 3-week treatment period of two treatment sessions per week.
One month after LI-ESWT, the erectile function in 15 men improved. An increase by more than five points in the International Index of Erectile Function – Erectile Function (IIEF-EF) domain score was noted in 14 men, and by more than 10 points in 7 men. Five men did not respond to LI-ESWT. Overall, the average increase in the IIEF-EF domain scores was 7.4 points (13.5–20.9, p = 0.001). Furthermore, erectile function and penile blood flow were measured using nocturnal penile tumescence (NPT) and venous occlusion plethysmography of the penis, respectively. LI-ESWT improved all NPT parameters, especially in the 15 men who responded to LI-ESWT, where significant increases in the duration of the erections and penile rigidity were recorded. Penile blood flow also improved significantly and a strong correlation was found between the increase in the IIEF-EF domain scores and the improvement in penile blood flow at the 1-month follow-up examination. At the 6-month follow-up visit, 10 men reported that they still had spontaneous erections that were sufficient for penetration and did not require PDE5i support.
In view of these very successful preliminary results, the effect of LI-ESWT was further investigated in a group of men whose ED was more severe than that of the first group of study patients [Gruenwald et al. 2012]. The average initial IIEF-EF domain score of the 29 men who were recruited for this second study was 8.8 ± 1. All 29 men had not responded to oral PDE5i therapy, and had multiple cardiovascular risk factors (23), cardiovascular disease (11), and diabetes mellitus (14). The specific aim of this second study was to investigate the ability of LI-ESWT to convert nonresponders to PDE5i therapy to PDE5i responders, so that they were able to achieve vaginal penetration with oral PDE5i therapy. The results were comparable to the first study. Three months after the completion of the LI-ESWT protocol, the IIEF-EF domain scores improved by at least five points in 22 men (76%) and the mean IIEF-EF domain score increased by 10 points (to 18.8 ± 1, p < 0.0001). At the end of the study, eight men (28%) achieved normal erections (IIEF-EF domain score greater than 25) and 21 of the 29 men were able to achieve vaginal penetration with oral PDE5i therapy. Overall, 21 men (72%) were converted to PDE5i responders. Cavernosal blood flow and penile endothelial function, as measured again by venous occlusion plethysmography of the penis (flow-mediated dilatation techniques [FMDs]), were both found to be significantly improved (p = 0.0001) in the men who responded to LI-ESWT. In both studies, a strong and significant correlation between the subjective assessment of sexual function using validated sexual function questionnaires and the objective results of penile blood flow and erectile function was found. Moreover, none of the men in both studies reported treatment-associated pain or any adverse events during or after the treatment. The encouraging results from these two studies led us to conduct a prospective, randomized, double-blind, sham-controlled study on 60 men with ED [Vardi et al. 2012]. In this study, we investigated the effects of LI-ESWT on erectile function and penile blood flow using the identical treatment protocol and study parameters that were used in our previous two studies. For the sham-treatment, we used a probe which did not produce any SW energy but looked identical to the treatment probe and produced the same noise and feeling of a ‘hit’. The demographic characteristics and the baseline mean IIEF-EF scores of the treated and sham-treated patients of this third study were similar. We found that mean IIEF-EF domain scores of the treated men were significantly higher than those of the sham-treated men. This increase in the IIEF-EF domain scores was also accompanied by improvements in cavernosal blood flows and penile endothelial function, as measured by venous occlusion plethysmography of the penis (FMD). We have been following most of these men for more than 2 years and they all report that the beneficial response that was achieved immediately after therapy has not waned (Table 1). Table 1. Table 1. The clinical studies included in the paper. Discussion The management of ED has remarkably evolved during the last decade and achieving high-quality erections has become reasonably simple for some men with ED since the introduction of PDE5is. Nevertheless, all current available treatment modalities for ED are basically ‘on-demand’ therapies and their mechanism of action is to improve a single sexual encounter. One of the main research goals of this coming decade is finding a cure for ED. The current lines of investigation into new ED therapies are based on the Rho-kinase pathway, as well as exploring the feasibility of gene therapy through intracorporeal injections of plasmids and stem cell regenerative therapy. The introduction of a new therapeutic modality for ED whose underlying mechanism of action is unclear or unproven certainly warrants skepticism and criticism. Hence, there are more questions than answers regarding the therapeutic use of LI-ESWT for ED. On the other hand, our consistent and repeatable results withstand these doubts because the results from our three different studies not only confirm each other, but also demonstrate that LI-ESWT has a genuine physiological effect on the erectile mechanism. Although our results are promising, they are still limited. More double-blind, randomized, controlled trials and long-term follow-up studies to confirm our findings are essential. There is also still much to investigate about the effect of LI-ESWT on the various types of ED, and the clinical parameters that could be used to predict who would benefit from LI-ESWT and who would not still require clarification, definition, and validation. There is also a need to determine the treatment protocols of LI-ESWT in order to establish the optimal protocol, in which the number of treatments and the number of penile sites to expose to LI-ESWT are defined. In this regard, we are already investigating different protocols and are offering a second 9-week treatment course for those who responded only partially to the first treatment course. Other studies are crucial for determining the optimal treatment protocol that will provide the best clinical outcome. Basic research is unquestionably required in order to explore and understand the mechanism of action of LI-ESWT on erectile tissue, as well as on other biologic systems. Conclusions LI-ESWT is a revolutionary treatment of ED, and probably possesses unprecedented qualities that can rehabilitate erectile tissue. The clinical improvement in subjective erectile function together with the significant improvement in penile hemodynamics following LI-ESWT confirm that LI-ESWT has unique properties that may create a new standard of care for men with ED. LI-ESWT is both feasible and tolerable and without any adverse or unwanted effects. Its main advantage is its ability to improve and potentially restore erectile function in men with ED without additional pharmacotherapy. Hence, LI-ESWT is an appealing addition to the armamentarium of existing treatment options for ED. In the near future we hope that LI-ESWT will be used for the long-term clinical management of ED either as an alternative or as an enhancer to the current treatments of ED.
Islamize Europe and get women out of politics. Feminism is the root if terrorism.
We, the elite, want all young beautiful women for us. Better not to tax alcohol and tobacco, as it removes low-quality men from the sexual arena. Also give them street drugs to ruin their health and lives.
Botox Claimed To Be A Treatment For Erectile Dysfunction
Erectile dysfunction is a condition that affects hundreds of millions of men. Many of these men could potentially permanently overcome their sexual dysfunction by changing their lifestyle and simply live a healthier life.
However, many men treat erectile dysfunction by using drugs like Pfizer Blue, Lilly’s Beige, and Bayer’s Beige. Now, there is also a new candidate for treating erectile dysfunction: Botox.
Please note that Truelibido does not support using pharmaceutical drugs or Botox to deal with erectile dysfunction. These remedies only treat symptoms but do nothing to permanently solve these problems.
Two Canadian urologists believe that the Botox injections can increase blood flow to the penis by paralyzing the nerves in the penis that instruct the smooth muscles to contract. The injection would last for about 6 months and patients would then need to get new injections every six months. The treatment is claimed to be safe and has not had any side effects.
We are highly skeptical. Keep in mind that Botox is a neurotoxin. It paralyzes the nerve system and is in some studies reported to not remain in the local area of injection, but can spread throughout the body.
In Uganda, rich fathers use super high dosages of butea superba combined with tongkat ali to turn their gay sons into heterosexual husbands.
Most European women have gang rape fantasies, because their vaginas are so big that there is space for two or more dicks.
Virginity for Sale: The Dark World of Forced Teen Prostitution
“In recent years, millions of women and girls have been trafficked across borders and within countries. The global trafficking industry generates an estimated 5 (billion) to 7 billion U.S. dollars each year, more than the profits generated by the arms and narcotics trades,” a February 2001 Asia Foundation and Horizons Project Population Council report said.
In the late 17th century, the brothel area of Kamathipura was established to service British troops in what was then called Bombay, India. In 2004, the cost to buy a trafficked girl from Nepal in what is now called Mumbai is 100,000 to 120,000 rupees ($2,004 to $2,405). Girls trafficked from Nepal are known as a tsukris. They have been “indentured” (forced) to work under a never-ending contract commonly found with human trafficking.
The industry in the trafficking of Nepali girls is a lucrative business, and it can include forced labor, domestic and factory work. Teenage girls are often used in the sex industries, though, because of the extreme profit for traffickers and the very low incidence of law enforcement against sex-industry racketeers.
Arresting the traffickers can be very tricky. In rural Nepal, this is a constant challenge because adequate police enforcement is often nonexistent. Seen only as an investment to brothel owners, trafficked girls, in addition to the daily sex-servicing of clients, are used by the brothel owners as “virgins” — owners attempt to sell a girl’s virginity over and over again. This insidious crime can be found throughout the back alleys of Mumbai.
So, why are most brothel owners interested much more in owning girls from Nepal versus girls from India?
Villages like Ichowk, Mahankal and Talmarang in the Sindhupalchok district in north-central Nepal are full of girls who are more than eager for a better life. The rural districts of Makwanpur, Dhading and Khavre are also very involved in the trafficking of girls.
Besides this, rural Nepalese girls are cheaper to buy, easier to control and enslave; they are known to be much more obedient and are considered more attractive for brothel owners who may want to resell them. Because of their naïveté, these girls are easier to cheat and to force into debt bondage because they have very little, if any, education, and they usually do not speak any of the native languages of India.
“Annually, according to U.S. government-sponsored research completed in 2006, approximately 800,000 people are trafficked across national borders, which does not include millions trafficked within their own countries. Approximately 80 percent of transnational victims are women and girls, and up to 50 percent are minors,” the U.S. Department of State reports in a 2008 study.
(On April 21, 2008, WNN correspondent Kamala Sarup organized a program on HIV/AIDS and trafficking in the district of Sindhupalchowk, Nepal. At the bottom of this article, she shares a firsthand story about the sex trafficking in Nepal.)
Easily Exploited Demographic
According to the Asia Foundation, a human rights advocacy group, many Nepali communities “recognize the role of social and economic hardships in vulnerability to trafficking. They also blame the immoral character of the trafficked girl herself. Girls who seek independence want exposure to the world outside.”
While girls are faced with desperate prospects in trying to “improve” their lives, they are many times “tempted by the prospect of gaining material benefits and are perceived as bad and more likely to be trafficked,” the Asia Foundation said.
Index of articles